Taiho Oncology and Taiho Pharmaceutical to Present Data from AZTOUND Trial Evaluating Oral Azacitidine and Cedazuridine in Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia at the 68th American Society of Hematology Annual Meeting

Posted on by sHq_LoGiNz

PRINCETON, N.J. & TOKYO–(BUSINESS WIRE)–Data from the AZTOUND trial evaluating oral azacitidine and cedazuridine in patients with MDS or CMML will be shared at the 68th ASH Annual Meeting.

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance (opens in a new tab)
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.